Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Merck, Medarex, And Massachusetts In Deal

by Ann M. Thayer
April 27, 2009 | A version of this story appeared in Volume 87, Issue 17

Merck & Co. has licensed technology developed by biotechnology firm Medarex and the Massachusetts Biologic Laboratories at the University of Massachusetts Medical School for fighting infectious diarrhea. Paying $60 million upfront, Merck will get rights to CDA-1 and CDB-1, a fully human monoclonal antibody duo designed to neutralize the bacterial A and B toxins in Clostridium difficile infections. Medarex and MBL could split another $165 million in milestone payments as well as royalties from product sales by Merck. The antibody combination has completed Phase II clinical trials.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.